Changes of Circulating MicroRNAs in Response to Treatment With Teriparatide or Denosumab in Postmenopausal Osteoporosis

What Was Tested

This observational study paper looks at Teriparatide.

To investigate the effect of two antiosteoporotic agents with opposite effects on bone metabolism on miR expression profile in the serum.

Why It Was Studied

Expression of microRNAs (miRs) related to bone metabolism in the serum may be affected by antiosteoporotic treatment.

Who Took Part

PubMed indexes the participants as middle-aged adults, older adults and people over 80, women only.

The outpatient clinics for Metabolic Bone Diseases of 424 General Military Hospital, Thessaloniki, Greece.

Postmenopausal women with low bone mass were treated with either teriparatide (TPTD; n = 30) or denosumab (n = 30) for 12 months.

How the Study Was Run

In design terms this was an open-label study.

Everyone knew when Teriparatide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The timeline in the abstract includes 12 months.

Observational, open label, nonrandomized clinical trial.

What Was Measured

The subject headings attached to it are Biomarkers, Bone Density, Bone Density Conservation Agents, Bone Remodeling, Circulating MicroRNA, Collagen Type I and Core Binding Factor Alpha 1 Subunit.

What This Means in Plain Language

The paper is an open-label study of Teriparatide over 12 months.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2018 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Teriparatide compound page, all human trials.